FL-MITSUBISHI-POWER
Today, PW Power Systems officially changed its name to Mitsubishi Power Aero. Adopting the Mitsubishi Power brand is part of a larger effort to apply synergies that will benefit aero-derivative gas turbine customers. The strength of the aero-derivative product and services portfolio will be enhanced by further leveraging the resources and technologies of Mitsubishi Power Aero’s parent company.
“We are utilizing Mitsubishi Power supply chain assets around the world to support new equipment manufacturing as well as aftermarket services,” said Mitsubishi Power Aero President and CEO Raul Pereda. “Our Engineering teams are collaborating to make our gas turbines more competitive, including applications with hydrogen fuel, remote monitoring, and TOMONITM artificial intelligence. The financial resources of the broader group also allow us to offer more flexible commercial solutions to our customers. We are eager to collaborate with our customers to deliver power when the world needs it most.”
As electrification expands and the demand for reliable energy grows globally, the role of aero-derivative on-demand power has become even more critical. The socioeconomic cost of power shortages is significant and rising, and power system complexity is increasing due to factors such as rapid expansion of renewables, extreme weather events, electrification of transportation, energy storage, and alternative fuels, including hydrogen. The flexible power generation solutions provided by Mitsubishi Power are essential to helping customers balance their diverse energy requirements.
“On-demand power is a key component in how Mitsubishi Power brings total solutions to our customers,” Paul Browning, President and CEO of Mitsubishi Power Americas, said. “The FT8® MOBILEPAC® unit offers fast, turnkey power on short notice, and the FT4000® SWIFTPAC® gas turbine provides super-flexible power to customers who want to increase their use of intermittent renewable power, such as wind and solar. As the pace of decarbonization of energy increases across the globe, aero-derivative power is crucial to ensuring resource adequacy. We’re excited about integrating our supply chain, manufacturing, engineering, marketing, sales, service, and financial capabilities with the strong products, services, and turnkey project capabilities of Mitsubishi Power Aero. Together, we will work with our customers to create a Change in Power .”
About Mitsubishi Power Americas, Inc.
Mitsubishi Power Americas, Inc. headquartered in Lake Mary, Florida, employs more than 2,000 power generation, energy storage, and digital solutions experts and professionals. Our employees are focused on empowering customers to affordably and reliably combat climate change while also advancing human prosperity throughout North and South America. Mitsubishi Power’s power generation solutions include natural gas, steam, aero-derivative, geothermal, distributed renewable technologies, environmental controls, and services. Energy storage solutions include green hydrogen and battery energy storage systems. Mitsubishi Power also offers digital solutions that enable autonomous operations and maintenance of power assets. Mitsubishi Power, Ltd. is a wholly owned subsidiary of Mitsubishi Heavy Industries, Ltd. (MHI). Headquartered in Tokyo, Japan, MHI is one of the world’s leading heavy machinery manufacturers with engineering and manufacturing businesses spanning energy, infrastructure, transport, aerospace and defense. For more information, visit the Mitsubishi Power Americas website and follow us on LinkedIn .
About Mitsubishi Power Aero LLC
Mitsubishi Power Aero LLC, headquartered in Glastonbury, Connecticut, USA, is a leader in the supply of fast-track, on-demand power solutions to global power producers and industrial and O&G customers. We provide flexible and customizable products and services, including aero-derivative gas turbine packages that generate 30 to 140 MW, tailored and responsive aftermarket services, turnkey EPC expertise, and battery storage. As the demand for electricity expands, and more renewables are added to power grids, Mitsubishi Power Aero will continue to play a vital role in providing energy security to customers around the world. Mitsubishi Power Aero is a group company of Mitsubishi Power Americas, Inc. Connect with us at aero.power.mhi.com and LinkedIn .
View source version on businesswire.com: https://www.businesswire.com/news/home/20210401005180/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
The Rock-It Company Expands Fine Art Logistics Capabilities of DIETL Through Acquisition of Several Strategic Infrastructure Services5.1.2026 15:00:00 CET | Press release
The acquisition strengthens DIETL’s fine art logistics operations through expanded access to specialized storage, handling and customs services. The Rock-It Company announced today that DIETL has acquired multiple fine art logistics specialists, strengthening its infrastructure and expanding access to specialized services across key U.S. art markets. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260105175923/en/ The Rock-It Company Expands Fine Art Logistics Capabilities of DIETL Through Acquisition of Several Strategic Infrastructure Services The acquired companies include Delaware Freeport, Delaware National Art Company, Techno Export, and Registrar Technologies. Together, these businesses add depth across fine art storage, handling, packing, crating, installation support, customs brokerage, and technology-enabled logistics services, complementing DIETL’s existing operations. Delaware Freeport, a provider of high-security
TII Launches Falcon Reasoning: Best 7B AI Model Globally, Also Outperforms Larger Models5.1.2026 14:54:00 CET | Press release
Falcon H1R 7B Packs Advanced Reasoning into a Compact 7 Billion Parameter Model Optimized for Speed and Efficiency TII’s Latest AI Model Outperforms Larger Rivals from Microsoft, Alibaba, and NVIDIA on Key Benchmarks The Technology Innovation Institute (TII), the applied research pillar of Abu Dhabi’s Advanced Technology Research Council (ATRC), has announced the release of Falcon H1R 7B, a next-generation AI model that takes a significant step toward making advanced AI more accessible than ever, by delivering world-class reasoning performance in a compact, efficient, and openly available format. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260105981339/en/ TII Launches Falcon Reasoning: Best 7B AI Model Globally, Also Outperforms Larger Models (Graphic: AETOSWire) With just 7 billion parameters, Falcon H1R 7B challenges and, in many cases, outperforms larger open-source AI models from around the world, including models fr
Curing the Incurable with ‘Biological Age Zero’ Cells: Clonell™ Launches the Ultimate Regenerative Medicine Platform5.1.2026 14:00:00 CET | Press release
Fundamental Cure for Intractable and Incurable Diseases using ‘Biological Age Zero’ Cells Derived from Patient’s Own Cells via SCNT TechnologyWorld's First Therapy Platform Simultaneously Solving Immune Rejection and Inheritance of Cellular Aging—The Major Hurdles of Existing Stem Cell TherapiesDrastically Improving Treatment Accessibility through the New Paradigm, ‘Patient-Initiated Clinical Trial™’, which Overcomes Existing Clinical Limitations Clonell Therapeutics, Inc., a leading biotechnology company dedicated to curing intractable and incurable diseases, announced today the official launch of the world's first 'Patient-Specific Embryonic Stem Cell (Somatic Cell Nuclear Transfer-derived Embryonic Stem Cell, hereinafter SCNT-ESC)' therapy platform based on Somatic Cell Nuclear Transfer (SCNT) technology. Concurrently, the company has initiated its innovative 'Patient-Initiated Clinical Trial™' to apply this breakthrough technology directly to patients. This platform launch is evalu
HELUS Pharma Propels Therapeutic Innovation in Mental Health and Commences Trading on Nasdaq5.1.2026 13:30:00 CET | Press release
Helus Pharma builds on the strong foundation originally created as Cybin Inc., reflecting the Company’s ongoing transformation to a commercial stage pharmaceutical company Helus Pharma commences trading on Nasdaq Global Market (“Nasdaq”) and on Cboe Canada under ticker symbol: HELP Helus Pharma continues to progress its portfolio of novel serotonergic agonists (“NSAs”), with the goal of developing treatments designed to redefine mental health care, including HLP004 for the treatment of generalized anxiety disorder, with Phase 2 topline data readout expected in Q1 2026 Preparations in progress for the commercialization of HLP003, Helus Pharma’s NSA in Phase 3 clinical development, which has been granted Breakthrough Therapy Designation by the FDA for the adjunctive treatment of major depressive disorder This news release constitutes a “designated news release” for the purpose of the Company’s prospectus supplement dated December 30, 2025, to it short form base shelf prospectus dated Sep
Incyte Announces Positive Topline Results from Pivotal Study of Tafasitamab (Monjuvi®/Minjuvi®) as a First-line Treatment for Diffuse Large B-Cell Lymphoma5.1.2026 13:30:00 CET | Press release
- Phase 3 frontMIND trial evaluating the efficacy and safety of tafasitamab (Monjuvi®/Minjuvi®) and lenalidomide in addition to R-CHOP met its primary endpoint of progression-free survival (PFS) - Based on these results, Incyte plans to file a supplemental Biologics License Application (sBLA) for tafasitamab and lenalidomide in addition to R-CHOP in first-line diffuse large B-cell lymphoma (DLBCL) in the first half of 2026 Incyte (Nasdaq:INCY) today announced positive topline results from the pivotal Phase 3 frontMIND trial evaluating the efficacy and safety of tafasitamab (Monjuvi®/Minjuvi®), a humanized Fc-modified cytolytic CD19 targeting monoclonal antibody, and lenalidomide in addition to R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone) compared to R-CHOP alone as a first-line treatment for adults with newly diagnosed diffuse large B-cell lymphoma (DLBCL) with an International Prognostic Index (IPI) score of three to five (3-5) for patients >60 years o
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom